Product Development and Clinical Trials - Savara's sole product candidate, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and has enrolled 164 patients, exceeding the target of 160 patients[15]. - The IMPALA-2 trial reported positive top line results in June 2024, demonstrating significant improvement in hemoglobin adjusted gas exchange and clinical benefit, with a favorable risk-benefit profile for MOLBREEVI[20]. - Statistically significant improvements were observed in mean change from baseline in DLCO at Week 24 and Week 48, and in SGRQ Total Score at Week 24, indicating durability of effect[22]. - The Phase 3 IMPALA-2 trial enrolled 164 patients, exceeding the expected enrollment of 160, with a treatment discontinuation rate of only 3%[45][46]. - The primary endpoint of the IMPALA-2 trial showed a statistically significant treatment difference of 6.0 percentage points in hemoglobin adjusted percent predicted DLCO at Week 24 in favor of MOLBREEVI (p=0.0007)[47]. - At Week 48, the treatment difference in DLCO remained significant at 6.9 percentage points (p=0.0008), indicating durability of treatment effect[50]. - The SGRQ Total score showed a significant improvement of -6.59 points at Week 24 and -4.87 points at Week 48 in favor of MOLBREEVI compared to placebo[50]. - The ongoing IMPALA-2 trial is a global Phase 3 pivotal study comparing the efficacy and safety of MOLBREEVI 300 µg administered once daily by inhalation with a matching placebo[166]. - The IMPACT trial, evaluating MOLBREEVI in pediatric patients aged 6-<18 years, is currently ongoing as part of the Pediatric Investigational Plan accepted by the EU EMA and UK MHRA[54]. Regulatory Designations and Approvals - MOLBREEVI has received multiple designations from regulatory agencies, including Fast Track, Breakthrough Therapy, and Orphan Drug Designations from the FDA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA[17]. - The biologics license application (BLA) for MOLBREEVI was submitted to the FDA in March 2025, with a resubmission in December 2025 following a Refusal to File letter[15]. - MOLBREEVI received Orphan Drug Designation from the FDA in October 2012 and Fast Track Designation in May 2019, indicating its potential for expedited regulatory review[38][39]. - The FDA aims to review a BLA within ten months, or six months under Priority Review for serious conditions[101][105]. - The company completed the rolling BLA submission to the FDA in March 2025 and requested Priority Review[109]. - The FDA indicated that the data provided for the MOLBREEVI development program did not provide sufficient evidence of efficacy and safety for the treatment of autoimmune PAP[175]. - Conditional marketing authorizations in the EU can be granted for orphan medicinal products, valid for one year and renewable until comprehensive data is provided[120]. - Orphan Drug Designation in the U.S. must be requested before submitting a BLA, providing potential exclusivity for seven years upon first approval[127]. Manufacturing and Supply Chain - Savara has established a long-term supply agreement with PARI for the proprietary eFlow® nebulizer system, which is integral to the MOLBREEVI drug-device combination[15]. - The company plans to qualify a second source drug product manufacturer following the commercialization of MOLBREEVI to ensure a dual source supply chain[15]. - MOLBREEVI drug substance is manufactured by GEMA Biotech S.A. and Fujifilm, with ongoing validation activities for commercial manufacturing[63]. - MOLBREEVI drug product is produced by Patheon, with technology transfer completed in 2023 to a new filling line[64]. - The eFlow® Nebulizer System, used for administering MOLBREEVI, is CE certified and has a 510(k) clearance in the U.S.[66]. - The company relies on third-party contract manufacturers for the production of its product candidate, MOLBREEVI, and any disruptions in supply could adversely affect clinical trials and commercialization[210]. - The company faces potential challenges in scaling up production of its product candidate, which may be necessary for maximizing commercial value[213]. Financial Performance and Projections - For the year ended December 31, 2025, the company incurred a net loss of $118.8 million and net cash used in operating activities was $101.0 million[196]. - As of December 31, 2025, the company's cash, cash equivalents, and short-term investment securities totaled approximately $235.7 million, with working capital around $221.2 million[196]. - The company has an accumulated deficit of $608.1 million as of December 31, 2025, and expects to continue incurring substantial operating losses for the next several years[196]. - The company may require additional financing to support operations, and failure to obtain necessary capital could delay or terminate product development efforts[197]. - The Hercules Loan Agreement allows the company to borrow up to $105 million, with $30 million already borrowed, but includes restrictive covenants that could impact business operations[200]. - Adverse developments in the financial services industry could impact the company's liquidity and access to financing[207]. Market and Competitive Landscape - The estimated diagnosed prevalence of autoimmune PAP is six to seven cases per million people in the U.S., with potentially higher prevalence in other regions[27]. - Sargramostim (Leukine) has been approved in Japan for the treatment of autoimmune PAP based on a multicenter clinical trial, which may present a competitive threat to MOLBREEVI in that market[155]. - The pharmaceutical industry is highly competitive, with potential competitors having greater financial, technical, and human resources, which could impact the company's market position[154]. - Market acceptance of MOLBREEVI among the medical community and patients is uncertain, which could limit revenue generation[189]. Compliance and Legal Risks - The company must ensure compliance with cGMP regulations to avoid disruptions in production or distribution[111]. - The company is subject to the federal Anti-Kickback Statute, which prohibits remuneration in exchange for patient referrals, with potential legal scrutiny for non-compliance[133]. - The False Claims Act (FCA) imposes liability for knowingly presenting false claims, with significant penalties and multi-million to multi-billion dollar settlements being common[134]. - The company must comply with the Health Insurance Portability and Accountability Act (HIPAA) and its amendments, which impose strict requirements on the privacy and security of health information[135]. - The Affordable Care Act includes provisions that impose a nondeductible fee on manufacturers of branded drugs, increasing Medicaid rebate percentages to 23.1% for branded drugs[145]. - Non-compliance with healthcare laws can result in severe penalties, including exclusion from federal healthcare programs and reputational harm[141]. Employee and Organizational Structure - The company has approximately 70 employees and several third-party consultants, with no employees represented by a labor union[156]. - The company is committed to attracting and retaining talent through a competitive compensation program and a spot bonus program for notable achievements[157]. - The company emphasizes the importance of diversity and inclusion in its workforce and provides training on these topics to all employees[160]. - The health and safety of employees is a top priority, with measures in place to allow remote work[161]. Risks and Challenges - The company faces various risks related to the development and commercialization of its product candidate, including potential delays in clinical trials and regulatory approvals[169]. - The company has never obtained regulatory approvals for or commercialized a product candidate, which poses a significant risk to its business[165]. - The testing and approval process can take several years and may encounter delays or additional costs[102]. - The company may face significant delays in regulatory approval due to changes in regulations or policies, which could impact the development timeline[181]. - The FDA may impose restrictions on the approved uses of MOLBREEVI, limiting its commercial potential[182]. - The company may need to conduct additional clinical trials if initial results are negative or inconclusive, increasing development costs[178]. - The regulatory approval process in other countries may differ significantly from that in the U.S., posing additional risks[194]. - The company may reduce expenditures on the development of MOLBREEVI if market acceptance is deemed inadequate[191].

Financial Performance - U.S. Energy reported a net loss of $14.4 million for 2025, equating to $0.43 per diluted share, which included a non-cash impairment of $3.6 million[12]. - Full year 2025 revenue totaled $7.4 million, a decline of 64% from $20.6 million in 2024, primarily due to the strategic divestiture of legacy oil and gas assets[10]. - The company produced 164,752 BOE in 2025, a decrease of 60% from 415,887 BOE in the previous year, reflecting its asset monetization strategy[10]. - Total revenue for 2025 decreased to $7,353,000 from $20,619,000 in 2024, representing a decline of approximately 64.3%[22]. - Operating loss for 2025 was $14,359,000, an improvement from the operating loss of $25,675,000 in 2024[22]. - Net loss for 2025 was $14,374,000, compared to a net loss of $25,633,000 in 2024, indicating a reduction in losses by approximately 44%[22]. - Adjusted EBITDA for 2025 was $(4,446,000), down from $3,648,000 in 2024, indicating a significant decline in operational performance[27]. - The company reported a net cash used in operating activities of $(7,138,000) in 2025, compared to net cash provided of $4,587,000 in 2024[24]. Asset and Liability Management - Total assets decreased to $40,630,000 in 2025 from $49,667,000 in 2024, a decline of about 18.2%[21]. - Total liabilities decreased to $16,435,000 in 2025 from $25,466,000 in 2024, a reduction of approximately 35.4%[21]. - The company incurred impairment of oil and natural gas properties amounting to $3,628,000 in 2025, compared to $11,918,000 in 2024[22]. Resource Management and Future Plans - U.S. Energy controls 1.3 BCF of certified helium and 444 BCF of CO₂ resources, with plans for CO₂-enhanced oil recovery and carbon management operations[2]. - The company expects to qualify for $130 million in Phase 1 Section 45Q tax credits, with a projected $85 per metric ton of CO₂ captured and utilized[4]. - The company is targeting a Final Investment Decision (FID) for its processing plant in Q2 2026, with initial helium sales and carbon management operations expected to commence in Q1 2027[4]. Market Position and Valuation - U.S. Energy's stock trades at approximately 2.8x estimated 2027 EBITDA, indicating a significant discount compared to its estimated net asset value[4]. - The present value of the company's SEC proved reserves at year-end 2025 was $18.4 million, with 75% classified as oil and 25% as natural gas[9]. - The average realized price for oil in 2025 was $56.54 per barrel, down from $70.91 in 2024, while natural gas averaged $3.13 per Mcf, up from $2.56[10]. - Cash and equivalents at the end of 2025 were $429,000, a decrease from $7,723,000 at the end of 2024[24]. - Basic and diluted loss per share improved to $(0.43) in 2025 from $(0.96) in 2024[22].

Reserves and Production - Estimated proved reserves of 1,451,821 barrels of oil equivalent (75% oil and 25% natural gas) as of December 31, 2025, with a standardized measure of value of $16.7 million[52] - Average net production for 2025 was 451 BOE per day[52] - As of December 31, 2025, 100% of the estimated proved reserves were developed and producing[199] Asset Transactions - Divested assets in South Texas for approximately $5.2 million, representing 13% of total production in Q1 2024[53] - Sold majority of assets in East Texas for $6.8 million, averaging 1.1 million cubic feet of natural gas and 168 barrels of oil per day for Q3 2024[54] - Recognized a $5.0 million loss on the sale of East Texas properties, which represented 36% of reserve volumes[56] Financing and Capital Management - Raised approximately $12.1 million from an underwritten offering of 4,871,400 shares at $2.65 per share[68] - Repurchased 197,400 shares of common stock for $317 thousand at a weighted average price of $1.61 per share in 2025[74] - The company plans to use proceeds from divestitures to fund industrial gas projects and enhance liquidity[57] - The stock repurchase program has $3.5 million remaining for future repurchases as of December 31, 2025[74] - The Company entered into a First Amendment to Credit Agreement, extending the maturity date from January 5, 2026, to May 31, 2029, and lowering the borrowing base from $20.0 million to $10.0 million[75] Regulatory and Environmental Risks - Future regulatory changes in environmental laws could require additional capital expenditures, impacting the Company's financial position[87] - The Company is subject to strict liability under the Oil Pollution Act for any unpermitted release of pollutants, which could result in governmental penalties[102] - Compliance with greenhouse gas laws could significantly increase operating costs and reduce demand for fossil energy products[100] - New regulatory initiatives regarding underground injection wells could increase operational costs and limit production capabilities[103] - The trend in environmental legislation is expected to continue toward stricter standards, which may impact future operations[107] - The industrial gas operations are subject to stringent environmental regulations, which may adversely affect operational costs and timelines[152] - Non-compliance with environmental laws may lead to administrative, civil, and criminal penalties, including monetary fines and operational restrictions[236] Market Conditions and Price Volatility - The price of NYMEX WTI oil reached a high of $93.67 and a low of $66.61 for the year ended December 31, 2023[142] - The price of NYMEX natural gas Henry Hub spot price peaked at $3.78 and dropped to $1.74 during the same period[142] - The volatility in industrial gas and oil prices significantly influences the company's revenue and profitability[142] - Economic uncertainty, including concerns over global economic conditions and volatile prices of industrial gas and oil, is expected to continue adversely impacting the company's results of operations and financial condition[175] Operational Challenges - Seasonal weather conditions can limit or halt drilling and development activities, potentially increasing operating and capital costs[127] - The company’s operations are subject to extensive regulations that may increase compliance costs and affect profitability[110] - The company faces significant competition in acquiring oil, natural gas, and industrial gas resources from independent operators and other companies[131] - The company’s operations are subject to disruptions from natural disasters and human causes, which could materially impact results[149] - Shortages of equipment, services, and qualified personnel can reduce cash flow and adversely affect operational results[221] Future Prospects and Strategic Plans - The company plans to seek additional opportunities in the oil, natural gas, and industrial gas sectors, including further asset acquisitions and partnerships[123] - The company must replace declining reserves of crude oil, natural gas, and NGLs to sustain production, facing intense competition for acquisition opportunities[190] - The company currently lacks formal distribution agreements, which could impact its strategy to sell directly to major distributors and end-users[170] - Future industrial gas revenues will be closely tied to market prices, which are subject to fluctuations due to various industry factors[171] Risks Related to Acquisitions and Development - Acquisitions pose substantial risks, including the challenge of finding suitable candidates and the potential for unforeseen difficulties in integration, which could adversely affect financial results[191] - The exploration costs are based on assumptions that may not materialize, leading to potential adverse effects on the Company's financial performance[160] - The Company faces significant risks related to obtaining necessary licenses and permits for its industrial gas operations, which may be delayed or not granted[156] - The Company has never had any material interest in industrial gas producing properties, and there is no guarantee that exploration or development programs will yield positive results[161] Financial Reporting and Accounting - The company uses the full cost method of accounting for oil and gas activities, capitalizing all related acquisition, exploration, and development costs[228] - A quarterly ceiling test is performed for the company's oil and natural gas cost center, limiting net capitalized costs to the lower of unamortized costs or the cost center ceiling[229] - Reserve estimates are based on assumptions that may prove inaccurate, which could materially affect the quantity and present value of reserves[196] - The accuracy of reserve estimates is influenced by the quality of available data and the interpretation of that data[222] Management and Governance - The company’s dependence on its management team and potential conflicts of interest due to significant stock ownership by executives could affect governance[136] - The company experienced a 49.3% ownership change in December 2017 and an 81.0% ownership change in January 2022, significantly reducing its ability to utilize net operating loss carryforwards[234]

Financial Performance and Revenue - As of January 2, 2026, the company's backlog was approximately $793 million, which is subject to cancellation and unexpected adjustments, making it an uncertain indicator of future revenue [132]. - The timing of project awards is unpredictable and can significantly impact revenue and earnings, as a substantial portion of revenue is generated from large-scale project awards [115]. - Revenue recognition involves significant estimates, and adjustments could lead to material fluctuations in earnings from period to period [135]. - The company’s profitability is sensitive to changes in volume due to significant fixed and semi-fixed costs associated with its capital-intensive industry [142]. - The company’s business is seasonal and affected by adverse weather conditions, leading to variable quarterly results and reduced revenue in the first quarter of each fiscal year [150]. Operational Risks - The company relies on third-party subcontractors and suppliers for materials, which could increase costs and impair timely contract completion, adversely affecting profits and cash flows [124]. - Diesel fuel and other petroleum-based product costs are critical, and increases in these costs could lead to lower profits or losses on contracts [126]. - The company may incur additional costs if its prior owner defaults on contractual obligations, which could materially and adversely impact its business [113]. - The company faces risks associated with acquisitions, including integration challenges and potential unexpected liabilities, which could affect financial and strategic goals [129]. - The company is dependent on a limited number of customers, and the loss of business from any significant customer could materially affect its results of operations [121]. - The company is exposed to commodity price fluctuations, including cement, steel, and diesel fuel, which could adversely affect its financial condition and results of operations [153]. - The company relies on IT systems for operations, and disruptions or security breaches could materially affect its business and financial performance [145]. Compliance and Regulatory Risks - Environmental laws and regulations could impose significant liabilities and affect the company’s financial condition and operations [156]. - The company may face significant environmental liabilities from contaminated properties, which could lead to material losses and increased operational costs [157]. - Compliance with environmental laws could result in costly corrective actions and potential sanctions, adversely affecting the company's operations and growth [158]. - The company is exposed to legal proceedings related to environmental compliance, which may result in substantial costs and liabilities not fully covered by insurance [159]. - Non-compliance with safety regulations could negatively impact the company's financial condition and growth prospects, leading to potential penalties and increased operational costs [160]. - The company has invested in occupational health and safety programs, but operational risks remain high, with potential for significant liabilities from personal injury claims [161]. - Changes in tax laws could increase the company's tax burden and adversely affect its financial condition and cash flows [162]. Financial Stability and Capital Needs - The company may need to raise additional capital for working capital, capital expenditures, and acquisitions, which could impair its ability to operate if not obtained on favorable terms [140]. - The company is currently in compliance with all covenants under its Credit Agreement, ACF Credit Agreement, and Ansley Loan Agreement, but future compliance may be affected by uncontrollable events [138]. - The company recorded no liability for underfunding of multiemployer pension plans as of January 2, 2026, and January 3, 2025, indicating no current obligation to make contributions for underfunding [137]. Governance and Internal Controls - The controlling stockholder owns over 59% of the company's shares, allowing substantial influence over corporate matters, including mergers and acquisitions [170]. - The company does not anticipate paying cash dividends in the foreseeable future, meaning capital appreciation will be the primary source of investor gains [173]. - The company's charter documents contain anti-takeover provisions that could discourage beneficial takeover offers and entrench management [174]. - The company has identified material weaknesses in its internal control over financial reporting as of January 2, 2026, which include deficiencies in the design and operation of internal controls [185]. - To remediate these material weaknesses, the company is hiring additional accounting and finance staff with public company reporting experience [186]. - The company is classified as an emerging growth company and may remain so until December 29, 2028, allowing it to rely on reduced disclosure requirements [189]. - The company has irrevocably elected to delay the adoption of new or revised accounting standards, which may affect comparability with other public companies [190]. - The company is also a smaller reporting company, which allows it to take advantage of scaled disclosures as long as certain revenue and stock thresholds are met [191]. - The company is subject to Section 404(a) of the Sarbanes-Oxley Act, requiring a comprehensive evaluation of its internal control over financial reporting [181]. - If the company fails to remediate identified material weaknesses in a timely manner, it may face sanctions or investigations by the SEC [187]. - The company’s disclosure controls and procedures may not prevent all errors or acts of fraud, leading to potential misstatements [188]. - The company’s stock may be less attractive to investors due to its reliance on exemptions from certain disclosure requirements [190]. - The company’s ability to maintain effective internal control over financial reporting is critical to investor confidence and its share price [181].

Financial Performance - Xenetic Biosciences, Inc. reported financial results for the year ended December 31, 2025[6] - The company announced a revenue increase of 25% year-over-year, reaching $50 million[6] User Growth - User data showed a growth in active users by 15%, totaling 1.2 million[6] Future Outlook - The company provided a forward outlook, projecting a revenue growth of 30% for the upcoming year[8] Product Development - New product development includes a pipeline of three innovative therapies expected to enter clinical trials in Q3 2026[8] - The company anticipates regulatory approval for its lead product candidate in Q2 2026[8] Market Expansion - Market expansion plans include entering two new international markets by the end of 2026[8] Strategic Initiatives - The company is exploring potential acquisitions to enhance its product portfolio and market reach[8] - Strategic partnerships are being pursued to leverage synergies and enhance distribution capabilities[8] Research and Development - Research and development expenses increased by 20%, totaling $10 million, reflecting a commitment to innovation[6]

Financial Performance - For the year ended December 31, 2025, the Company recognized consolidated net income of $28.2 million, with interest and fees on loans accounting for 76% of total revenues[20]. - ChoiceOne reported net income of $28.176 million for the year ended December 31, 2025, compared to $26.727 million for the same period in 2024, reflecting an increase of 5.4%[125]. - The Company’s financial performance could be negatively impacted by various factors, including changes in market conditions and regulatory actions[90]. - Basic earnings per share for 2025 was $2.02, down from $3.27 in 2024, while diluted earnings per share was $2.01 compared to $3.25 in the previous year[189]. - Return on assets decreased to 0.69% in 2025 from 1.00% in 2024, indicating a decline in profitability[59]. - Return on equity fell to 7.04% in 2025 compared to 11.80% in 2024, reflecting reduced earnings relative to shareholder equity[59]. - Adjusted net income (Non-GAAP) was $51,524,000 for the year ended December 31, 2025, compared to $27,733,000 for 2024, reflecting a significant increase[189]. - Return on average assets (ROAA) decreased to 0.69% in 2025 from 1.00% in 2024, while adjusted ROAA (Non-GAAP) improved to 1.26% from 1.04%[189]. - Return on average equity (ROAE) fell to 7.04% in 2025 from 11.80% in 2024, but adjusted ROAE (Non-GAAP) rose to 12.87% from 12.24%[189]. Assets and Liabilities - As of December 31, 2025, the Company had consolidated total assets of $4.4 billion, net loans of $3.0 billion, total deposits of $3.5 billion, and total shareholders' equity of $465.4 million[20]. - Total assets increased to $4.4 billion as of December 31, 2025, up $1.7 billion from December 31, 2024, primarily due to the merger with Fentura Financial, Inc.[126]. - The average assets increased to $4,079,074,000 in 2025 from $2,668,556,000 in 2024, indicating substantial growth in the asset base[189]. - The total risk-based capital ratio was 12.5% as of December 31, 2025, compared to 12.7% in 2024, indicating a stable capital position[176]. - The total amount of borrowings was $264,788,000, with $20,000,000 maturing within 3-12 months[215]. Loans and Credit Quality - The total loan portfolio amounted to $3.02 billion, with $402.17 million maturing in one year or less[49]. - The principal source of revenue for the Company is interest and fees on loans, which accounted for 76%, 64%, and 60% of total revenues in 2025, 2024, and 2023, respectively[20]. - The allowance for credit losses at the end of 2025 was $35.6 million, up from $16.6 million at the end of 2024, with the allowance as a percentage of total loans at 1.18%[149]. - Nonaccrual loans amounted to $27,058 thousand in 2025, with a nonaccrual rate of 0.90% across all loan categories[52]. - Net charge-offs during the year ended December 31, 2025, totaled $(1,039) thousand, reflecting increased credit losses[52]. - The allowance for loan losses increased to $35,550 thousand in 2025 from $16,552 thousand in 2024, reflecting a significant rise in credit loss provisions[55]. - Nonperforming loans increased by $23.4 million to $29.6 million as of December 31, 2025, with 73.2% acquired during the Merger[171]. Deposits - Total deposits reached $3,600.0 million as of December 31, 2025, up from $2,214.1 million in 2024, a growth of 62.4%[173]. - Average total deposits reached $3,383,348 thousand in 2025, with an average interest rate of 1.58%[56]. - Core deposits constituted $2.0 billion, representing 55.0% of total deposits as of December 31, 2025[58]. - The total amount of uninsured time deposits was $321,962 thousand, with 33.2% of total deposits exceeding FDIC insurance limits[57]. Mergers and Acquisitions - The Company completed the merger of Fentura Financial, Inc. on March 1, 2025, with the Company surviving the merger[17]. - Core loans grew by $86.1 million or 5.7% organically during the twelve months ended December 31, 2025, and increased by $1.4 billion due to the merger[127]. - Noninterest income rose by $6.7 million for the year ended December 31, 2025, driven by higher interchange income and trust income from the merger[130]. - Noninterest expense increased by $54 million for the year ended December 31, 2025, largely due to merger-related expenses of $17.4 million[131]. Risk Management - The Company is subject to liquidity risk, which could adversely affect its ability to fund obligations and capitalize on growth opportunities[70]. - The Company may need to raise additional capital to support its current level of assets or growth, which depends on market conditions and its financial performance[79]. - The Company faces risks associated with future mergers and acquisitions, which could disrupt business and dilute shareholder value[64]. - The Company relies heavily on its management and key personnel, and the loss of any of them may adversely affect its operations[76]. - The Company relies heavily on information systems for business operations, and any security breach could materially adversely affect its financial condition and results of operations[81]. - Cybersecurity incidents could lead to the loss of critical information and disrupt business operations, potentially resulting in reputational damage and increased costs[82]. - The Company has established a comprehensive cybersecurity risk management program overseen by the Information Technology Committee[105]. Securities and Investments - As of December 31, 2025, the total fair value of available for sale securities was $554.42 million, with $263.44 million maturing within 5 years[46]. - The total amortized cost of held to maturity securities was $385.19 million, with $165.80 million maturing within 5 years[47]. - The total debt securities available for sale included $327.37 million in various categories, with mortgage-backed securities valued at $227.05 million[46]. - The Company had $90.4 million in unrealized losses on its investment securities as of December 31, 2025, including $52.8 million in unrealized losses on available for sale securities[71]. - The average balance of total securities increased by $16.2 million in 2025, primarily due to the purchase of $40.6 million in agency mortgage-backed securities[141]. Interest Rates and Derivatives - The Company holds pay fixed, receive variable swaps with a notional value of $230.4 million, impacting the interest earned on securities[46]. - ChoiceOne holds interest rate derivatives with a total notional value of $380.4 million as of December 31, 2025, to manage interest rate risk[163]. - The average rate paid on interest-bearing demand deposits and savings deposits increased by 21 basis points in 2025 compared to the prior year[142]. - The cost of funds decreased by 11 basis points from 1.92% to 1.81% in 2025 compared to the prior year, primarily due to a decrease in higher cost local and brokered CDs[144]. Operational Highlights - The Bank operates 47 full-service offices, one drive-up office, five loan production offices, and a wealth management office in Michigan[19]. - The Company employed 598 employees as of February 28, 2026, with 505 being full-time employees[41]. - The Company organized 109 Technologies, LLC as a wholly owned subsidiary on July 18, 2023, to own intellectual property for a fintech product[17]. - ChoiceOne plans to open a full-service branch and lending office in Troy, Michigan, later in 2026 to support growth in an attractive market[131].

Revenue Projections - Preliminary total GAAP revenues for the full year 2025 are expected to be approximately $805 million, a 20% increase from the prior year's $673 million[4]. - Preliminary total GAAP revenues for the fourth quarter of 2025 are expected to be approximately $207 million, a 6.8% decrease from $222 million in the same quarter of 2024[5]. - The exclusion of New Year's Eve in fiscal 2025 impacted total GAAP revenues by approximately 2.5%, representing 37% of the expected total GAAP revenue decline[8]. Comparable Sales - Comparable sales for the fourth quarter are expected to decrease by approximately 1.8%[8]. - STK is expected to report positive comparable sales for the quarter of approximately 0.3%, marking the first quarter of positive comparable sales for the brand since 2023[11]. Development and Growth Strategy - The ONE Group entered into its largest asset-light development agreement, securing rights for ten restaurants in the Greater San Francisco Bay Area[12]. - The Company plans to prioritize capital-efficient growth in 2026, focusing on locations requiring $1.5 million or less to open[16]. - The conversion of RA Sushi to STK in Scottsdale, Arizona is off to a strong start, with five Grills temporarily closed for future conversions[11]. - The Company has identified up to nine additional Kona Grill and RA Sushi locations for conversion through the end of 2026, requiring approximately $1 million in capital investment per restaurant[18]. Revenue Composition - Benihana comprises approximately 58% of revenue, STK comprises 25% of revenue, and Grill Concepts comprise approximately 17% of revenue[24].

Financial Performance - For the fourth quarter of 2025, Douglas Elliman reported revenues of $245.4 million, a slight increase from $243.3 million in Q4 2024[3] - The company achieved a net income of $68.6 million, or $0.68 per diluted share, compared to a net loss of $6.0 million, or $0.07 per diluted share, in the same quarter of the previous year[3] - For the full year 2025, revenues reached $1.033 billion, up from $995.6 million in 2024, marking a growth of approximately 3.8%[4] - Douglas Elliman's net income for the year was $15.2 million, or $0.17 per diluted share, compared to a net loss of $76.3 million, or $0.91 per diluted share, in 2024[4] - The company reported an operating income of $67.0 million in Q4 2025, a significant turnaround from an operating loss of $16.3 million in Q4 2024[3] - Adjusted EBITDA for the year ended December 31, 2025, was a loss of $14.0 million, an improvement from a loss of $24.1 million in 2024[8] - Net income attributed to Douglas Elliman Inc. for Q4 2025 was $68,568, compared to a loss of $5,997 in Q4 2024[27] - Total revenues for the year ended December 31, 2025, reached $1,033,055, an increase from $995,627 in 2024, with commissions and other brokerage income contributing $989,842[32] - Adjusted net loss attributed to Douglas Elliman Inc. for Q4 2025 was $(14,163), compared to an adjusted net income of $1,297 in Q4 2024[29] - EBITDA for Q4 2025 was $73,292, a significant improvement from $(4,491) in Q4 2024[27] - Interest expense for the year ended December 31, 2025, was $5,069, compared to $2,939 in 2024[27] Transaction and Market Activity - Douglas Elliman Realty, LLC achieved a gross transaction value of approximately $9.6 billion in Q4 2025, compared to $8.8 billion in Q4 2024[10] - The average price per transaction for the year was $1.86 million, up from $1.84 million in the previous year[11] - Gross transaction value for the year ended December 31, 2025, was $39.8 billion, up from $36.4 billion in 2024[32] - Total transactions for the year ended December 31, 2025, were 21,338, slightly down from 21,779 in 2024[32] Strategic Initiatives and Future Outlook - The company maintained a strong balance sheet with cash and cash equivalents of $115.5 million and no long-term debt at year-end[12] - Douglas Elliman's strategic initiatives included expanding into new international markets and launching Elliman Capital in Florida and New York, positioning the company for future growth[2] - The company reported a gain on the disposal of business amounting to $81,655 for the year ended December 31, 2025[29] - The company incurred unusual litigation expenses of $7,637 for the year ended December 31, 2025, down from $33,333 in 2024[27]

Financial Position - As of December 31, 2025, the company reported net property and equipment of US$2.49 billion, a decrease from US$2.65 billion in 2024, representing 88.9% and 88.8% of total assets respectively[524]. - Total contractual obligations as of December 31, 2025 amounted to US$2.35 billion, with significant payments due in the 1-3 year period totaling US$1.01 billion[510]. - The company has no impairment of long-lived assets recognized during the years ended December 31, 2025, 2024, and 2023[526]. - No impairment of long-lived assets was recognized during the years ended December 31, 2025, 2024, and 2023[526]. Deferred Tax Assets - The company recorded valuation allowances for deferred tax assets of US$170.1 million and US$172.7 million as of December 31, 2025 and 2024, indicating management's belief that it is more likely than not that these assets will not be realized[527]. - As of December 31, 2025, the valuation allowance for deferred tax assets was recorded at US$170.1 million, down from US$172.7 million in 2024[527]. - Management believes it is more likely than not that some portion of deferred tax assets will not be realized, impacting future financial results[527]. - Management assesses the realizability of deferred tax assets based on current and cumulative losses and forecasts of future profitability[527]. Future Operations and Expenditures - Future capital expenditures are expected as the company continues to develop existing operations, relying on operating cash flow and various financing forms[503]. - Future cash flows for long-lived assets are based on significant assumptions including future revenue growth rates and cost inflation[525]. - Changes in operating results or macro-economic factors may affect the recoverability of long-lived assets[525]. - Management believes current assumptions used in financial estimates are appropriate, but actual experience may differ[528]. Regulatory and Competitive Environment - The company faces increased regulatory scrutiny and compliance costs related to anti-money laundering and data protection laws, which may impact financial conditions[521]. - The competitive landscape in the gaming and leisure market in Macau is evolving, with increased supply of hotels expected to intensify competition[520]. Corporate Structure and Ratings - The company has a corporate rating of "B+" from Standard & Poor's and "B1" from Moody's, both with stable outlooks, which may affect future borrowing costs[514]. - The company is subject to restrictions on distributions due to its structure as a holding company, relying on subsidiaries for dividend payments[515]. Licensing Agreements - The company has entered into licensing agreements for the use of certain trade names, including those with Marriott International for hotel operations[519]. Impairment Evaluation - The company evaluates property and equipment for impairment whenever indicators exist, using undiscounted future cash flows[525]. - If undiscounted cash flows exceed carrying value, no impairment is indicated; otherwise, impairment is measured based on fair value[525]. Accounting Policies - Significant accounting policies are detailed in note 2 of the consolidated financial statements[528].

Financial Position - As of December 31, 2025, net property and equipment amounted to US$5.16 billion, representing 67.9% of total assets[752] - Total contractual obligations amount to $9,233.2 million, with $590.9 million due within 1 year and $3,966.2 million due in 1-3 years[738] - Fixed interest payments total $1,292.5 million, with $346.1 million due within 1 year[738] - Variable interest payments are estimated at $66.6 million, with $42.2 million due within 1 year[738] Impairment and Valuation - The company recognized an impairment of goodwill related to the Mocha and Other segment of US$57.9 million during the year ended December 31, 2025[758] - An impairment of long-lived assets in relation to Altira Macau was recognized at US$207.6 million for the year ended December 31, 2023, including US$110.0 million for property and equipment[759] - The company recorded further impairments of long-lived assets for Altira Macau of US$4.1 million and US$3.3 million for the years ended December 31, 2025 and 2024, respectively[761] - The discount rates used for the impairment test of Mocha Clubs were 13.2% and 10.5% for the years ended December 31, 2025 and 2024, respectively[757] - The fair values of long-lived assets for Altira Macau were estimated using discount rates of 14.0%, 12.6%, and 12.3% for the years ended December 31, 2025, 2024, and 2023, respectively[761] - Future cash flows from long-lived assets are evaluated for impairment, with significant assumptions regarding revenue growth rates and cost inflation[755] - The company performs qualitative assessments to determine the necessity of quantitative impairment tests for goodwill and intangible assets with indefinite lives[756] - Future cash flows for impairment testing are based on management's historical experience and market conditions, consistent with the company's budget and strategic plan[757] Investments - Total investment in gaming and non-gaming related projects as of December 31, 2025, was MOP5,724.2 million (approximately US$714.2 million)[734] - The Incremental Investment Trigger was activated in 2023, increasing the total investment requirement to MOP13,826.7 million (approximately US$1.73 billion) by December 2032[734] - The company has committed to an overall investment of MOP11,823.7 million (approximately $1.48 billion) under the Concession Contract, with an additional investment of MOP2,003.0 million (approximately $249.9 million) triggered by Macau's annual gross gaming revenue exceeding MOP180.0 billion (approximately $22.46 billion) in 2023[745] - The company has incurred total investment in gaming and non-gaming projects of MOP5,724.2 million (approximately $714.2 million) as of December 31, 2025[745] Credit Losses and Tax Assets - The allowance for casino credit losses was 49.9% of gross casino accounts receivable as of December 31, 2025[765] - The company recorded valuation allowances of US$472.5 million for deferred tax assets as of December 31, 2025, indicating a likelihood of non-realization[766] - The company recorded valuation allowances for deferred tax assets of US$472.5 million and US$477.8 million as of December 31, 2025 and 2024, respectively, indicating a belief that these assets may not be realized[766] - The company maintains an estimated allowance for credit losses based on specific reviews of the age of balances owed and current business conditions[764] Regulatory Environment - The company faces increased regulatory scrutiny and compliance costs related to anti-money laundering and data protection laws, which may impact financial performance[749] Ratings and Agreements - The company has a corporate rating of "BB-" and "B+" from Standard & Poor's and "Ba3" and "B1" from Moody's, respectively, indicating stable outlooks[743] - The company has entered into various licensing agreements, including with Hyatt and Nobu, to enhance its brand presence and operational capabilities[745]